1.36 USD
↗ 0.04 (3.03%)AT CLOSE (11:59 AM EDT)
ADC Therapeutics SA
ADCTNYSE • USD
1.35
↘ 0.01 (0.52%)
POST MARKET (AS OF 08:15 PM EDT)
Post Market
AS OF 08:15 PM EDT
1.35
↘ 0.01 (0.52%)
Market: CLOSED
ADC Therapeutics SA (ADCT) is currently trading at $1.36. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, exceptional Return on Equity (42.5%) and a bearish Death Cross on the long-term moving averages. Valuation metrics suggest ADCT is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Sep 4, 2026.
Open?$1.30
High?$1.37
Low?$1.30
Prev. Close?$1.32
Volume?1.5M
Avg. Volume?1.5M
VWAP?$1.34
Rel. Volume?0.97x
Bid / Ask
Bid?$1.31 × 200
Ask?$1.40 × 4.2K
Spread?$0.09
Midpoint?$1.36
Valuation & Ratios
Market Cap?173.6M
Shares Out?127.7M
Float?95.0M
Float %?74.7%
P/E Ratio?N/A
P/B Ratio?-0.76
EPS?-$0.76
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Employees
193
Market Cap
173.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2020-05-15
Address
BIOPOLE
EPALINGES, V8 1066
Phone: 41 21 653 02 00
EPALINGES, V8 1066
Phone: 41 21 653 02 00
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?0
Momentum?33
Short Sent.?33
Piotroski F-Score?2/9Weak
Altman Z-Score?-8.38Distress
Confidence?64%Moderate
Short InterestHigh
Short % of Float?6.50%Elevated
Short Interest?6.2M
Days to Cover?6.3
Free Float95.0M
Avg Daily Volume979.8K
Settlement Date2026-08-14
Financial Health
Current Ratio?3.03Strong
Quick Ratio?2.97Strong
Cash Ratio?2.54Strong
Debt/Equity?-0.51Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?-0.76CHEAP▾
S&P97
P/S?2.18CHEAP▾
Peers100
S&P63
P/FCF?N/A▾
EV/EBITDA?-0.7CHEAP▾
S&P97
EV/Sales?0.89CHEAP▾
Peers100
S&P93
Returns & Efficiency
ROE?42.5%STRONG▾
Peers50
S&P90
ROA?-34.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-102302000
Enterprise Value?$71.1M
Fundamentals ratios updated end of day